Proffitt & Goodson Inc Genmab A/S Transaction History
Proffitt & Goodson Inc
- $694 Million
- Q3 2025
A detailed history of Proffitt & Goodson Inc transactions in Genmab A/S stock. As of the latest transaction made, Proffitt & Goodson Inc holds 62 shares of GMAB stock, worth $1,799. This represents 0.0% of its overall portfolio holdings.
Number of Shares
62Holding current value
$1,799% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding GMAB
# of Institutions
252Shares Held
65.2MCall Options Held
32.5KPut Options Held
55K-
Alliancebernstein L.P. New York, NY10.7MShares$310 Million0.08% of portfolio
-
Orbis Allan Gray LTD Hamilton, D07.92MShares$230 Million1.07% of portfolio
-
Black Rock Inc. New York, NY5.08MShares$147 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il3.57MShares$104 Million0.01% of portfolio
-
Arrowstreet Capital, Limited Partnership Boston, MA3.45MShares$100 Million0.05% of portfolio
About GENMAB A/S
- Ticker GMAB
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 658,292,992
- Market Cap $19.1B
- Description
- Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...